Chemotherapy with cisplatinum, carboplatin and 5FU-folinic acid, followed by concomitant chemo-radiotherapy in unresectable esophageal carcinomas;Chimiothérapie par une association de cisplatine, carboplatine et 5-fluoro-uracile-acide folinique, suivie de chimioradiothérapie dans les cancers de l'œsophage inopérables

Bulletin du Cancer

Volumn 88, Issue 2, 2001, Pages 203-207

  Hennequin, C ^a   Salemkour, A ^a   Mal, F ^a   Lecomte, T ^a   Boudet, M J ^a   Perniceni, T ^a   Gayet, B ^a   Maylin, C ^a   Raymond, E ^a  

^a SAINT LOUIS HOSPITAL   (France)

Author keywords

Carboplatin; Cisplatin; Esophageal carcinomas

Indexed keywords

CARBOPLATIN; CISPLATIN; FLUOROURACIL; FOLINIC ACID;

ADULT; ARTICLE; BOLUS INJECTION; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; DEATH; ESOPHAGUS CARCINOMA; HUMAN; INFECTION; LYMPHOCYTOPENIA; METASTASIS; NEUTROPENIA; SURVIVAL TIME; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CISPLATIN; COMBINED MODALITY THERAPY; ESOPHAGEAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; KIDNEY; LEUCOVORIN; LYMPHOPENIA; MALE; MIDDLE AGED; NEUTROPENIA; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; THROMBOCYTOPENIA;

EID: 0035074434     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Chemo-radiotherapy versus control group in advanced esophageal carcinoma
2. Contributions of chemotherapy in the treatment of carcinoma of the esophagus: Results and commentary
3. Traitement du cancer de l'œsophage
4. Randomised phase II study of cisplatin and 5-fluorouracil (5FU) versus cisplatin alone in advanced squamous cell oesophageal cancer
5. Carboplatin: A new platinum analog in the treatment of epidermoid carcinoma of the esophagus
6. Platinum analogue combination chemotherapy: Cisplatin and carboplatin: A phase I trial with pharmacokinetics assessment of the effect of cisplatin administration on carboplatin excretion
7. Clinical benefit with cisplatin, hydroxyurea and 5fluorouracil/leucovorin in advanced pancreatic adenocarcinoma
8. Pharmacokinetic study in carboplatin, cisplatin and 5-fluorouracil regimen for advanced oesophageal cancer
9. Phase II trial of carboplatin plus cisplatin in recurrent and advanced squamous cell carcinoma of the head and neck
10. Combined-modality therapy in the treatment of loco-régional oesophageal cancer
11. A phase II evaluation of high dose cisplatin and etoposide in patients with advanced esophageal adenocarcinoma
12. Phase II trial of dose intensification with cisplatin and carboplatin plus vindesine in patients with inoperable non-small cell lung cancer
13. Pharmacokinetic study in carboplatin, cisplatin and 5-fluorouracil regimen for advanced oesophageal cancer
14. Final report of Intergroup trial 0122 (ECOG PE-289, RTOG 90-12): Phase II trial of neoadjuvant chemotherapy plus concurrent chemotherapy and high-dose radiation for squamous cell carcinoma of the esophagus
15. Platinum-DNA adducts in leukocyte DNA correlates with disease response in ovarian cancer patients receiving platinum-based chemotherapy
16. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil and methotrexate in advanced squamous-cell carcinoma of the head and neck: A Southwest Oncology Group Study
17. A phase II trial of carboplatin and vinblastine in the treatment of advanced squamous cell carcinoma of the esophagus
18. Radiation therapy alone or with concurrent low-dose daily either with cisplatin or carboplatin in locally advanced unresectable squamous cell carcinoma of the head and neck: A prospective randomized trial
19. Split-course accelerated radiation therapy combined with carboplatin and 5-fluorouracil for palliation of metastatic or unresectable carcinoma of the esophagus
20. Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus
21. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus
22. Reporting cancer treatment
23. Nonparametric estimation for incomplete observations